PBTC Open Protocol Summaries
 

Protocol Study Chair Information for
Patients and Families
Information for
Health Professionals
PBTC-026:
A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
J. Russell Geyer, MD
Seattle Children's Hospital
Seattle, WA.
Phone: (206) 987-6664
Email: russ.geyer@seattlechildrens.org
Summary for Patients and Families Abstract for Health Professionals
PBTC-029B:
A Phase 1 and Phase II Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Anu Banerjee, MD
University of California San Francisco (UCSF)
San Francisco, CA.
Phone: (415) 476-3831
Email: banerjee@neurosurg.ucsf.edu
Summary for Patients and Families Abstract for Health Professionals
PBTC-033:
A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
Patricia A. Baxter, MD
Texas Children's Cancer Center
Houston, TX.
Phone: (832) 824-4681
Email: pabaxter@txch.org
Summary for Patients and Families Abstract for Health Professionals
PBTC-037:
A phase I study of intratumoral/peritumoral herpes simplex virus-1 mutant HSV1716 in patients with refractory or recurrent high grade gliomas (HGG) - This study is only active at Cincinnati Children’s Hospital Medical Center.
Mariko DeWire, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH.
Phone: (513) 636-4266
Email: mariko.dewire@cchmc.org
Summary for Patients and Families Abstract for Health Professionals
PBTC-039:
A Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma
Regina Jakacki, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA
Phone: (412) 692-7056
Email: regina.jakacki@chp.edu
Summary for Patients and Families Abstract for Health Professionals
PBTC-041:
A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors
Stewart Goldman, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Phone: (312) 227-4844
Email: sgoldman@luriechildrens.org
Summary for Patients and Families Abstract for Health Professionals
PBTC-042:
A Phase I study of CDK4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Sridharan Gururangan, MRCP (UK)
Duke University Medical Center
Durham, North Carolina 27710
Phone: (919) 668-6288
Fax: (919) 668-2485
Email: Sridharan.gururangan@duke.edu
Summary for Patients and Families Abstract for Health Professionals

 
PBTC Closed Protocol Summaries
 

Protocol Study Chair Information for
Health Professionals
PBTC-001:
Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals
PBTC-002:
A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors
Mark W. Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals
PBTC-003:
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors
Mark W. Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals
PBTC-004:
Phase I Study of Intrathecal SpartajectTM-Busulfan in Children with Neoplastic Meningitis
Sri Gururangan, MRCP (UK)
Duke University Medical Center
Durham, NC.
Phone: (919) 668-6288
Email: gurur002@mc.duke.edu
Abstract for Health Professionals
PBTC-005:
Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-3604
Email: amar.gajjar@stjude.org
Abstract for Health Professionals
PBTC-006:
A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas
Ian F. Pollack, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA.
Phone: (412) 692-5881
Email: ian.pollack@chp.edu
Abstract for Health Professionals
PBTC-007:
 A Phase I/II Trial of ZD1839 (IressaTM) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II limited to Brain Stem Tumors
J. Russell Geyer, MD
Seattle Children's Hospital
Seattle, WA.
Phone: (206) 987-6664
Email: russ.geyer@seattlechildrens.org
Abstract for Health Professionals
PBTC-009:
Phase I Trial of GLIADEL® and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas
Ian F. Pollack, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA.
Phone: (412) 692-5881
Email: ian.pollack@chp.edu
Abstract for Health Professionals
PBTC-010:
 A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma,
Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors
Maryam Fouladi, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-2094
Email: maryam.fouladi@stjude.org
Abstract for Health Professionals
PBTC-011C:
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma
Anuradha Banerjee, MD, MPH
University of California, San Francisco
San Francisco, CA.
Phone: (415) 353-2966
Email: Banerjee@neurosurg.ucsf.edu
Abstract for Health Professionals
PBTC-012:
Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors
Tobey MacDonald, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 884-2146
Email: tmacdona@cnmc.org
Abstract for Health Professionals
PBTC-013:
A Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-
a and a Mutated Form of the Pseudomonas Exotoxin Termed PE38 (TP-38) in Pediatric Patients with Recurrent or Progressive Supratentorial High Grade Gliomas
Roger Packer, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 884-2120
Email: rpacker@cnmc.org
Abstract for Health Professionals
PBTC-014:
Phase I/II Trial of Zarnestra and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
Daphne Haas-Kogan, MD
University of California, San Francisco
San Francisco, CA.
Phone: (415) 353-7175
Email: hkogan@radonc17.ucsf.edu
Abstract for Health Professionals
PBTC-015:
A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors
Kathy Warren, MD
National Cancer Institute
Pediatric-Oncology Branch
Bethesda, MD.
Phone: (301) 402-6298
Email: warrenk@mail.nih.gov
Abstract for Health Professionals
PBTC-016:
A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma
Maryam Fouladi, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-2094
Email: maryam.fouladi@stjude.org
Abstract for Health Professionals
PBTC-017:
Phase I Study of CLORETAZINE ™ (VNP4010M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors
Sri Gururangan, MRCP (UK)
Duke University Medical Center
Durham, NC.
Phone: (919) 668-6288
Email: gurur002@mc.duke.edu
Abstract for Health Professionals
PBTC-018:
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors
Kathy Warren, MD
National Cancer Institute
Pediatric-Oncology Branch
Bethesda, MD.
Phone: (301) 402-6298
Email: warrenk@mail.nih.gov
Abstract for Health Professionals
PBTC-019:
A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals
PBTC-020:
A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors
Mark Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals
PBTC-021:
A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals
PBTC-022:
 Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Sri Gururangan, MRCP (UK)
Duke University Medical Center
Durham, NC.
Phone: (919) 668-6288
Email: gurur002@mc.duke.edu
Abstract for Health Professionals
PBTC-023:
Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals
PBTC-024:
A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
Maryam Fouladi, MD
Cincinnati Children's Hospital Medical Center,
Cincinnati, OH.
Phone: (513) 636-4266
Email: maryam.fouladi@cchmc.org
Abstract for Health Professionals
PBTC-025:
A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals
PBTC-025B:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals
PBTC-027:
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors
Jack Su, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4306
Email: jmsu@txccc.org
Abstract for Health Professionals
PBTC-030:
A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas
Lindsay Kilburn, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 476-2800
Email: LKilburn@childrensnational.org
Abstract for Health Professionals
PBTC-031:
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors
Roger Packer, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 476-5973
Email: rpacker@cnmc.org
Abstract for Health Professionals
PBTC-032:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
St. Jude Children's Research Hospital
Memphis, TN
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals

 

PBTC Web Site

Introduction to PBTC

News & Updates

Protocol Summaries

Institutions' Contacts

Submitting Concepts

Giving Opportunities

Links to Resources

PBTC Members' Area